Physician profile
Brian E Gibson
NPI 1740257138
$1,853.48
in general payments reported to CMS, 2019-2025
19 companies · $853 in 2025
The $853 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.60 · 2020: $17.64 · 2021: $20.61 · 2022: $50.33 · 2023: $227 · 2024: $634 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.93 | 2023-2025 | |
| Lilly USA, LLC | $307.82 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $194.92 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.57 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $104.09 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $96.92 | 2019-2025 | |
| Amgen INC. | $82.78 | 2024-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $63.15 | 2024-2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.44 | 2019-2025 | Jardiance |
| Corium, LLC | $39.31 | 2024-2025 | Azstarys |
| Ibsa Pharma INC. | $33.61 | 2025 | Tirosint, Licart, Flector |
| Exact Sciences Corporation | $32.46 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Cequr Corporation | $25.92 | 2024 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $20.28 | 2023 | |
| Abbott Laboratories | $19.59 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.83 | 2025 | Trintellix |
| Amarin Pharma, INC. | $15.72 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.09 | 2024 | Qelbree |
| Idorsia Pharmaceuticals US INC | $14.05 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.